Pangali EV/EBITDA: Puma Biotechnology Inc (PBYI)

The share price retrospective for Puma Biotechnology (PBYI) demonstrates an EV/EBITDA multiple of 7.95. The business relies on the sale of Nerlynx, where patent protection guarantees a stable cash flow and high margins. Puma Biotechnology (PBYI) operates within a secure legal framework that precludes trade sanctions. High confidence within the medical community regarding the brand's targeted developments ensures the success of innovative treatment methods for specific forms of oncology.

PBYI Puma Biotechnology, Inc.: Nilai perusahaan marang bathi operasional sadurunge panyusutan ing interval 23.11.2025 - 10.11.2026

PBYI (pumabiotechnology.com): rincian analitis lan laporan miturut indikator

- rega saiki lan proyeksi nilai saham:

Rega saham Puma Biotechnology, Inc.|PBYI - Target konsensus

- indikator kapitalisasi bursa perusahaan:

Kapitalisasi pasar PBYI|PBYI - Nilai Perusahaan

- statistik nilai buku emiten:

Aset Bersih saben Siji Saham Puma Biotechnology|PBYI - Kapitalisasi Akuntansi|Rasio Kapitalisasi Pasar marang Nilai Buku pumabiotechnology.com|PBYI - Gunggung Aset Perusahaan

- indikator beban kredit lan likuiditas emiten:

Total Utang marang Modal Puma Biotechnology|PBYI - Kewajiban jangka dawa marang modal|Utang jangka cendhak marang ekuitas Puma Biotechnology, Inc.|PBYI - Kewajiban utang agregat|Rasio utang marang kapitalisasi buku PBYI|PBYI - Kewajiban jangka dawa|Kewajiban jangka cendhak perusahaan Puma Biotechnology|Likuiditas cepet pumabiotechnology.com

- data bathi bisnis lan rasio investasi:

PBYI - Penghasilan resik|Proyeksi bathi mangsa ngarep Puma Biotechnology|PBYI - Pangali P/E|Prakiraan rega marang bathi Puma Biotechnology, Inc.|PBYI - Koefisien bali modal nimbang wutah|Pangali EV/EBITDA PBYI|PBYI - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi resik saben saham (EPS TTM) Puma Biotechnology|PBYI - Bathi resik saben saham sajrone patang kuartal pungkasan|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan pumabiotechnology.com|PBYI - Kacepetan wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi saben saham kanggo taun ngarep Puma Biotechnology

Ringkesan analisis perusahaan:PBYI (Puma Biotechnology Inc)

Puma Biotechnology's high authority in breast cancer therapy ensures stable demand for its developments. The company's current EV/EBITDA value of 7.95 reflects the ratio of total enterprise value to operating profit before taxes and amortization. This metric allows for an assessment of the asset's real value accounting for debt load while excluding the influence of tax policy. Such an approach confirms the resilience of the issuer's financial model.

Pesaing langsung

Pangali EV/EBITDA OLMA (Olema Pharma)|GLSI - Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan|Zentalis Pharmaceuticals - Pangali EV/EBITDA|MGNX - Pangali EV/EBITDA|plustherapeutics.com (PSTV) - Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan|Nilai perusahaan marang bathi operasional sadurunge panyusutan PCSA|EGRX (Eagle Pharmaceuticals Inc.) - Pangali EV/EBITDA